Researchers have identified that the Ebola virus recruits a host enzyme, PP2A-B56, for replication, demonstrating that inhibiting this pathway could be a target for drug discovery.
Researchers have reported an acceptable safety and immunogenicity profile of an Ebola vaccine in adults and potentially in children in Africa – indicating that the vaccine produces an immune response and is considered safe.
A new study has identified the role of T cell protein, Tim-1, in initiating the inflammatory response that is central to Ebola pathogenesis and disease severity.
Researchers have examined the cerebrospinal fluid in a small cohort of Ebola survivors, reporting that no viral RNA was present and suggesting the virus may be cell-associated within the CNS.
A live-attenuated Ebola vaccine has demonstrated promising results in a Phase I randomized controlled trial assessing safety and immunogenicity, according to a Canadian study.
Researchers investigating Ebola virus have uncovered the function of delta protein, which is released in high levels during infection, and findings suggest it could play a crucial role in disease pathology.
Researchers examining post-Ebola syndrome have discovered ocular consequences, including a disease-associated retinal scar.
International collaborative research has analyzed Ebola virus genomes from the 2013–2016 outbreak, uncovering the role of factors such as language and distance between cities.
Although understanding of Ebola virus pathogenesis has rapidly increased recently, many questions relating to the role of the vascular system remain unanswered. The authors here discuss how Ebola virus infection can cause endothelial dysfunction and coagulopathy.
A Phase I clinical trial has demonstrated two investigational Ebola vaccines generate a durable immune response 1 year after vaccination.